STOCK TITAN

[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Bio-Rad Laboratories (BIO) reported an insider equity event by its President & COO. On 10/24/2025, 1,869 shares of Class A common stock were acquired at $0 upon the vesting of restricted stock units, followed by a disposition of 950 shares under code F at $339.75 per share. Following these transactions, 919 Class A shares are held directly.

The related RSU line shows 1,869 underlying shares delivered and 5,609 RSUs remaining outstanding. The RSUs vest over four years at 25% per year on the yearly anniversary of the grant.

Bio-Rad Laboratories (BIO) ha segnalato un cambio azionario interno da parte del suo President & COO. Il 24/10/2025 sono state acquisite 1.869 azioni ordinarie di Classe A a $0 al vesting delle unità azionarie vincolate, seguite da una cessione di 950 azioni sotto codice F a $339,75 per azione. Dopo queste operazioni, 919 azioni Classe A sono detenute direttamente.

La linea RSU correlata mostra 1.869 azioni sottostanti consegnate e 5.609 RSU rimaste in circolazione. Le RSU maturano nel corso di quattro anni al 25% all'anno nel giorno anniversario della concessione.

Bio-Rad Laboratories (BIO) informó un evento de acción de insider por parte de su Presidente y Director de Operaciones (COO). El 24/10/2025, se adquirieron 1.869 acciones ordinarias de Clase A a $0 al vesting de unidades de acciones restringidas, seguido de una disposición de 950 acciones bajo el código F a $339,75 por acción. Tras estas operaciones, se poseen directamente 919 acciones de Clase A.

La línea relacionada de RSU muestra 1.869 acciones subyacentes entregadas y 5.609 RSU pendientes en circulación. Las RSU se consolidan a lo largo de cuatro años al 25% por año en el aniversario anual de la concesión.

Bio-Rad Laboratories (BIO)은 사장 겸 COO에 의한 내부자 지분 이벤트를 보고했습니다. 2025년 10월 24일, 제한 주식의 가속 vesting으로 1,869주 의 Class A 일반 주식이 $0에 매입되었고, 이어서 코드 F에 따라 주당 $339.75로 950주가 처분되었습니다. 이 거래 이후 직접 보유하는 Class A 주식은 919주입니다.

관련 RSU 라인은 1,869주가 전달되었고 남은 RSU는 5,609주임을 보여줍니다. RSU는 부여일의 매년 기념일에 25%씩 4년에 걸쳐 vest됩니다.

Bio-Rad Laboratories (BIO) a signalé un événement d'actionnariat interne par son Président et COO. Le 24/10/2025, 1 869 actions ordinaires de Classe A ont été acquises à 0 $ lors de la prise en vesting des unités d’actions restreintes, suivies d’une cession de 950 actions sous le code F à 339,75 $ par action. Suite à ces transactions, 919 actions de Classe A sont détenues directement.

La ligne RSU associée affiche 1 869 actions sous-jacentes livrées et 5 609 RSU encore en circulation. Les RSU se vests sur quatre ans à raison de 25 % par an à la date anniversaire de la concession.

Bio-Rad Laboratories (BIO) meldete eine Insider-Eigenkapital-Transaktion durch seinen Präsidenten und COO. Am 24.10.2025 wurden 1.869 Class-A-Stammaktien zu $0 im Vesting von Restricted Stock Units erworben, gefolgt von einer Veräußerung von 950 Aktien unter dem Code F zu $339,75 je Aktie. Nach diesen Transaktionen halten sich direkt 919 Class-A-Aktien.

Die zugehörige RSU-Linie zeigt 1.869 zugrunde liegende Aktien geliefert und 5.609 RSUs verbleibend ausstehend. Die RSUs vesten über vier Jahre zu 25% pro Jahr am jährlichen Jubiläum der Gewährung.

Bio-Rad Laboratories (BIO) أبلغت عن حدث حقوق ملكية داخلي من قبل رئيسها والمدير التنفيذي للعمليات. في 24/10/2025، تم شراء 1,869 سهم عادي من الفئة أ بمبلغ 0$ عند احتساب وحدات الأسهم المقيدة، تلاها تحويل 950 سهماً وفق الرمز F بسعر 339.75$ للسهم. عقب هذه المعاملات، يصبح لدى 919 سهماً من الفئة A مملوكة بشكل مباشر.

تظهر سطر RSU المرتبط 1,869 سهماً أساسيًّا تم تسليمها و5,609 RSU معلقة في التداول. تتوزع RSUs على مدى أربع سنوات بنسبة 25% سنوياً عند ذكرى منحها.

Positive
  • None.
Negative
  • None.

Insights

Routine RSU vesting with share withholding; no open‑market sale indicated.

Bio-Rad reports a standard equity compensation event: 1,869 Class A shares issued at $0 from RSU vesting on 10/24/2025. A code M entry reflects settlement of RSUs into shares, consistent with the filing’s explanation.

A code F disposition of 950 shares at $339.75 occurred the same day, a method commonly used to cover obligations, without indicating an open‑market sale. Post‑event holdings show 919 non‑derivative shares and 5,609 RSUs remaining, with vesting at 25% annually over four years.

Bio-Rad Laboratories (BIO) ha segnalato un cambio azionario interno da parte del suo President & COO. Il 24/10/2025 sono state acquisite 1.869 azioni ordinarie di Classe A a $0 al vesting delle unità azionarie vincolate, seguite da una cessione di 950 azioni sotto codice F a $339,75 per azione. Dopo queste operazioni, 919 azioni Classe A sono detenute direttamente.

La linea RSU correlata mostra 1.869 azioni sottostanti consegnate e 5.609 RSU rimaste in circolazione. Le RSU maturano nel corso di quattro anni al 25% all'anno nel giorno anniversario della concessione.

Bio-Rad Laboratories (BIO) informó un evento de acción de insider por parte de su Presidente y Director de Operaciones (COO). El 24/10/2025, se adquirieron 1.869 acciones ordinarias de Clase A a $0 al vesting de unidades de acciones restringidas, seguido de una disposición de 950 acciones bajo el código F a $339,75 por acción. Tras estas operaciones, se poseen directamente 919 acciones de Clase A.

La línea relacionada de RSU muestra 1.869 acciones subyacentes entregadas y 5.609 RSU pendientes en circulación. Las RSU se consolidan a lo largo de cuatro años al 25% por año en el aniversario anual de la concesión.

Bio-Rad Laboratories (BIO)은 사장 겸 COO에 의한 내부자 지분 이벤트를 보고했습니다. 2025년 10월 24일, 제한 주식의 가속 vesting으로 1,869주 의 Class A 일반 주식이 $0에 매입되었고, 이어서 코드 F에 따라 주당 $339.75로 950주가 처분되었습니다. 이 거래 이후 직접 보유하는 Class A 주식은 919주입니다.

관련 RSU 라인은 1,869주가 전달되었고 남은 RSU는 5,609주임을 보여줍니다. RSU는 부여일의 매년 기념일에 25%씩 4년에 걸쳐 vest됩니다.

Bio-Rad Laboratories (BIO) a signalé un événement d'actionnariat interne par son Président et COO. Le 24/10/2025, 1 869 actions ordinaires de Classe A ont été acquises à 0 $ lors de la prise en vesting des unités d’actions restreintes, suivies d’une cession de 950 actions sous le code F à 339,75 $ par action. Suite à ces transactions, 919 actions de Classe A sont détenues directement.

La ligne RSU associée affiche 1 869 actions sous-jacentes livrées et 5 609 RSU encore en circulation. Les RSU se vests sur quatre ans à raison de 25 % par an à la date anniversaire de la concession.

Bio-Rad Laboratories (BIO) meldete eine Insider-Eigenkapital-Transaktion durch seinen Präsidenten und COO. Am 24.10.2025 wurden 1.869 Class-A-Stammaktien zu $0 im Vesting von Restricted Stock Units erworben, gefolgt von einer Veräußerung von 950 Aktien unter dem Code F zu $339,75 je Aktie. Nach diesen Transaktionen halten sich direkt 919 Class-A-Aktien.

Die zugehörige RSU-Linie zeigt 1.869 zugrunde liegende Aktien geliefert und 5.609 RSUs verbleibend ausstehend. Die RSUs vesten über vier Jahre zu 25% pro Jahr am jährlichen Jubiläum der Gewährung.

Bio-Rad Laboratories (BIO) أبلغت عن حدث حقوق ملكية داخلي من قبل رئيسها والمدير التنفيذي للعمليات. في 24/10/2025، تم شراء 1,869 سهم عادي من الفئة أ بمبلغ 0$ عند احتساب وحدات الأسهم المقيدة، تلاها تحويل 950 سهماً وفق الرمز F بسعر 339.75$ للسهم. عقب هذه المعاملات، يصبح لدى 919 سهماً من الفئة A مملوكة بشكل مباشر.

تظهر سطر RSU المرتبط 1,869 سهماً أساسيًّا تم تسليمها و5,609 RSU معلقة في التداول. تتوزع RSUs على مدى أربع سنوات بنسبة 25% سنوياً عند ذكرى منحها.

Bio-Rad Laboratories (BIO) 报告称其总裁兼首席运营官发生了内部人权益事件。在 2025/10/24,1,869 股 A 类普通股在限制性股票单位归属时以0美元购入,随后以 F 代号以每股339.75美元处置了950股。交易完成后,直接持有919股A类股票。

相关的 RSU 线显示交付了1,869股基础股票,尚未发行的RSU为5,609股。RSU 将在四年内按每年25% 的比例在授予日的周年日归属。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DiVincenzo Jonathan P.

(Last) (First) (Middle)
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE

(Street)
HERCULES CA 94547

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President & COO
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Bio-Rad A Common Stock 10/24/2025 M 1,869(1) A $0 1,869 D
Bio-Rad A Common Stock 10/24/2025 F 950 D $339.75 919 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0(2) 10/24/2025 M 1,869 (3) (3) Bio-Rad A Common Stock 1,869 $0 5,609 D
Explanation of Responses:
1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Remarks:
/s/ Jonathan P. DiVincenzo 10/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BIO report on this Form 4?

Vesting of restricted stock units into 1,869 Class A shares on 10/24/2025, plus a 950-share disposition under code F at $339.75.

How many Bio-Rad (BIO) shares does the reporting person now hold?

The reporting person holds 919 shares of Class A common stock directly after the reported transactions.

How many RSUs remain after this transaction for BIO?

The filing lists 5,609 restricted stock units remaining beneficially owned following the reported transactions.

What does transaction code M signify in this context?

Code M indicates settlement of a derivative security; here, 1,869 RSUs converted into Class A shares at $0.

What does transaction code F indicate for the BIO Form 4?

Code F reflects a disposition of 950 shares at $339.75 per share to satisfy obligations via share delivery/withholding.

What is the RSU vesting schedule noted by BIO?

The RSUs vest over four years at 25% per year on the yearly anniversary of the grant date.
Bio Rad Labs Inc

NYSE:BIO

BIO Rankings

BIO Latest News

BIO Latest SEC Filings

BIO Stock Data

8.94B
18.50M
16.24%
89.63%
3.71%
Medical Devices
Laboratory Analytical Instruments
Link
United States
HERCULES